Sra. Cristina Adame Castillo

Institutions of which it is part

I am a biologist especialised in molecular biology with certain experience in neurodegenerative diseases field. I have focused my career on the pharmaceutical industry, which has provided me with a great insight in how this industry invests in innovation and offers novel therapeutic options to patients. Currently, I work for the liver diseases research group supporting them in their daily duties and also boosting their activity to position ourselves as reference center national and internationally.

Curriculum

Project Manager (VHIR-Liver Diseases Group) - Nov 2021-Current
Business Development Manager (Trifermed) - Jul 2018-Nov 2021
MBA pharma & biotech industries (ESAME) - 2017-2018
In-Licensing Trainee (Kern Pharma) - Nov 2017-Jul 2018
Master degree in biochemistry, molecular biology and biomedicine (UAB) - 2015-2016
Degree in Biologia (UAB) - 2011-2015
Assistant Laboratory Technician - Neurodegenerative diseases (Hospital Germans Trias i Pujol) - Jul 2014-Oct 2014 and Feb 2016-Jul 2016
Cristina Adame Castillo

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.